Q-omics provides the consensus-scored ST8SIA5 profile across patient tissues and cancer cell-line models. ST8SIA5 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, ST8SIA5 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, ST8SIA5 protein abundance shows 16,826 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, KIRP, and PDAC as cancer lineages where ST8SIA5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ST8SIA5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ST8SIA5 survival associations across molecular data types. ST8SIA5 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ST8SIA5 RNA expression–survival associations across cancer types. High ST8SIA5 expression shows unfavorable associations in ACC, LGG and UCEC, but favorable associations in KIRP, LIHC and THCA. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for ST8SIA5 RNA expression.
This table summarizes ST8SIA5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ST8SIA5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ST8SIA5 shows lower tumor expression in KIRP, KIRC and COAD and higher tumor expression in KICH, BRCA and LIHC. The KIRP box plot shows higher ST8SIA5 RNA expression in normal versus tumor tissue (log2 FC = −0.579, t-test p < 0.001).
This table shows molecular features associated with ST8SIA5 in patient tissues and cancer cell lines. In patient samples, ST8SIA5 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, ST8SIA5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
